CA2964785A1 - Gene modified immune effector cells and engineered cells for expansion of immune effector cells - Google Patents

Gene modified immune effector cells and engineered cells for expansion of immune effector cells Download PDF

Info

Publication number
CA2964785A1
CA2964785A1 CA2964785A CA2964785A CA2964785A1 CA 2964785 A1 CA2964785 A1 CA 2964785A1 CA 2964785 A CA2964785 A CA 2964785A CA 2964785 A CA2964785 A CA 2964785A CA 2964785 A1 CA2964785 A1 CA 2964785A1
Authority
CA
Canada
Prior art keywords
cells
car
cell
antigen
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2964785A
Other languages
English (en)
French (fr)
Inventor
Laurence J.N. Cooper
Harjeet Singh
Helen HULS
Simon Olivares
Bipulendu JENA
Krina PATEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CA2964785A1 publication Critical patent/CA2964785A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4204—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2964785A 2014-11-05 2015-11-05 Gene modified immune effector cells and engineered cells for expansion of immune effector cells Abandoned CA2964785A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201462075667P 2014-11-05 2014-11-05
US201462075642P 2014-11-05 2014-11-05
US201462075561P 2014-11-05 2014-11-05
US62/075,561 2014-11-05
US62/075,667 2014-11-05
US62/075,642 2014-11-05
US201562169979P 2015-06-02 2015-06-02
US62/169,979 2015-06-02
PCT/US2015/059293 WO2016073755A2 (en) 2014-11-05 2015-11-05 Gene modified immune effector cells and engineered cells for expansion of immune effector cells

Publications (1)

Publication Number Publication Date
CA2964785A1 true CA2964785A1 (en) 2016-05-12

Family

ID=54548288

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2964785A Abandoned CA2964785A1 (en) 2014-11-05 2015-11-05 Gene modified immune effector cells and engineered cells for expansion of immune effector cells

Country Status (9)

Country Link
US (2) US20170333480A1 (OSRAM)
EP (2) EP3215535A2 (OSRAM)
JP (2) JP2017535284A (OSRAM)
KR (1) KR20170075785A (OSRAM)
CN (1) CN107207615A (OSRAM)
AU (2) AU2015343013B2 (OSRAM)
CA (1) CA2964785A1 (OSRAM)
HK (1) HK1243441A1 (OSRAM)
WO (1) WO2016073755A2 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3773918A4 (en) * 2019-03-05 2022-01-05 Nkarta, Inc. ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150320799A1 (en) 2012-12-20 2015-11-12 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
WO2014117121A1 (en) 2013-01-28 2014-07-31 St. Jude Children's Research Hospital, Inc. A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
KR102238226B1 (ko) 2013-05-14 2021-04-09 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 가공된 키메라 항원 수용체 (ｃａｒ) ｔ-세포의 인간 적용
SG11201509609SA (en) 2013-05-24 2015-12-30 Univ Texas Chimeric antigen receptor-targeting monoclonal antibodies
AU2015218239B2 (en) 2014-02-14 2019-01-31 Board Of Regents, The University Of Texas System Chimeric antigen receptors and methods of making
CN106459914B (zh) 2014-05-15 2020-11-06 新加坡国立大学 经修饰的自然杀伤细胞及其用途
WO2016073629A1 (en) 2014-11-05 2016-05-12 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) to selectively target protein complexes
PT3240805T (pt) 2014-12-15 2025-01-28 Univ California Recetor de antigénio quimérico de porta ou biespecífico responsivo a cd19 e cd20
EP3234120B1 (en) 2014-12-15 2025-09-03 The Regents of the University of California Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
EP3261656B1 (en) 2015-02-24 2020-08-19 Board of Regents, The University of Texas System Selection methods for genetically-modified t cells
PL3268470T3 (pl) 2015-03-11 2021-06-14 Board Of Regents, The University Of Texas System Polipeptydy transpozazy i ich zastosowania
WO2017222593A1 (en) * 2016-06-24 2017-12-28 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars), compositions and methods thereof
HK1258218A1 (zh) 2015-09-15 2019-11-08 Board Of Regents, The University Of Texas System T細胞受體(tcr)結合抗體及其應用
EP3368075B1 (en) 2015-10-27 2020-01-29 Board of Regents, The University of Texas System Chimeric antigen receptor molecules and uses thereof
EP3439675A4 (en) 2016-04-08 2019-12-18 Purdue Research Foundation METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
CN110191898B (zh) 2016-06-08 2024-05-10 英特瑞克斯顿股份有限公司 Cd33特异性嵌合抗原受体
CN106117366A (zh) * 2016-06-24 2016-11-16 安徽未名细胞治疗有限公司 一种cd19特异性嵌合抗原受体及其编码基因、应用
US11701384B2 (en) 2016-09-02 2023-07-18 The Regents Of The University Of California Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
WO2018064602A1 (en) * 2016-09-30 2018-04-05 Baylor College Of Medicine Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease
AU2017352591B2 (en) 2016-11-07 2024-07-11 Genovie Ab A two-part device for T-cell receptor synthesis and stable genomic integration to TCR-presenting cells
EP4332226A3 (en) * 2016-11-07 2024-05-08 Genovie AB An engineered two-part cellular device for discovery and characterisation of t-cell receptor interaction with cognate antigen
KR102833088B1 (ko) * 2016-11-07 2025-07-10 제노비에 에이비 T-세포 수용체 및 t-세포 항원의 식별 및 특징규명을 위한 조작된 다성분 시스템
CN108276493B (zh) * 2016-12-30 2023-11-14 南京传奇生物科技有限公司 一种嵌合抗原受体及其应用
CN118406655A (zh) 2017-01-10 2024-07-30 普瑞赛格恩公司 通过新基因开关表达系统调节多肽的表达
CN108424458A (zh) * 2017-02-13 2018-08-21 上海恒润达生生物科技有限公司 靶向ny-eso-1的嵌合抗原受体及其用途
EP3589295B1 (en) 2017-02-28 2024-09-11 Endocyte, Inc. Compositions and methods for car t cell therapy
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
MX2019011514A (es) 2017-03-27 2020-01-27 Nat Univ Singapore Receptores quimericos nkg2d truncados y usos de los mismos en inmunoterapia con celulas asesinas naturales.
CN110494557A (zh) 2017-03-27 2019-11-22 新加坡国立大学 用于离体扩增和活化自然杀伤细胞的刺激细胞系
ES2905377T3 (es) * 2017-04-18 2022-04-08 Autolus Ltd Célula
CN110997920A (zh) 2017-06-07 2020-04-10 英特拉克森公司 新型细胞标签的表达
TW201908335A (zh) * 2017-07-25 2019-03-01 美國德州系統大學評議委員會 增強之嵌合抗原受體及其用途
GB201713078D0 (en) * 2017-08-15 2017-09-27 Adaptimmune Ltd T Cell Modification
KR102809909B1 (ko) * 2017-09-29 2025-05-22 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 P53 암-특이적 돌연변이에 대한 항원 특이성을 갖는 t 세포를 단리하는 방법
EP3710471A1 (en) * 2017-11-16 2020-09-23 Kite Pharma, Inc. Modified chimeric antigen receptors and methods of use
CN108103106A (zh) * 2018-01-09 2018-06-01 河南省华隆生物技术有限公司 一种pFTM3GW重组载体及其制备方法和应用
CA3089319A1 (en) * 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
CN110093351B (zh) * 2018-01-29 2023-06-23 华南生物医药研究院 可分离的核酸、多肽、重组载体、重组细胞及应用
SG11202007156QA (en) 2018-02-09 2020-08-28 Nat Univ Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
CA3090512A1 (en) 2018-02-09 2019-08-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tethered interleukin-15 and interleukin-21
JP7568224B2 (ja) 2018-02-23 2024-10-16 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための配列決定法
WO2019182425A1 (ko) * 2018-03-23 2019-09-26 주식회사 에스엘바이젠 신규 키메라 항원 수용체 암호화 유전자가 형질도입된 유전자 변형 nk 세포주 및 그의 용도
JP7334985B2 (ja) 2018-04-02 2023-08-29 ナショナル ユニヴァーシティー オブ シンガポール 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
CA3103610A1 (en) * 2018-06-12 2019-12-19 The Regents Of The University Of California Single-chain bispecific chimeric antigen receptors for the treatment of cancer
EP3815711A4 (en) * 2018-06-29 2022-08-10 Taiho Pharmaceutical Co., Ltd. ANTITUMOR AGENT AND ITS METHOD OF EVALUATION
CN112513256A (zh) 2018-07-13 2021-03-16 国立大学法人京都大学 γδT细胞的制造方法
WO2020044239A1 (en) 2018-08-29 2020-03-05 National University Of Singapore A method to specifically stimulate survival and expansion of genetically-modified immune cells
EP3847266A1 (en) * 2018-09-05 2021-07-14 GlaxoSmithKline Intellectual Property Development Ltd T cell modification
TW202031679A (zh) * 2018-10-26 2020-09-01 日商橘生藥品工業股份有限公司 高效率之基因改造細胞之製作方法
CN111378046B (zh) * 2018-12-27 2024-03-15 上海细胞治疗集团有限公司 一种免疫效应细胞转换受体
KR20220030205A (ko) * 2019-02-08 2022-03-10 디앤에이 투포인토 인크. 면역 세포의 트랜스포존 기반 변형
CN111544585B (zh) * 2019-02-11 2024-12-27 北京卡替医疗技术有限公司 一种可助推免疫细胞在体内扩增的佐剂
WO2020178738A1 (en) * 2019-03-04 2020-09-10 University Health Network T cell receptors and methods of use thereof
EP3935176A4 (en) 2019-03-04 2022-12-28 University Health Network T-CELL RECEPTORS AND METHODS OF USE THEREOF
CN113710688A (zh) * 2019-03-26 2021-11-26 加利福尼亚大学董事会 用于治疗血液癌症和实体瘤癌症的嵌合抗原受体修饰的t细胞(car-t)
WO2021019706A1 (ja) * 2019-07-31 2021-02-04 国立大学法人信州大学 Ｃａｒ発現免疫細胞を含む細胞集団の製造方法
CN110592014A (zh) * 2019-08-14 2019-12-20 广东美赛尔细胞生物科技有限公司 一种在nk细胞治疗中免辐照体外体内持续去除饲养细胞的方法
WO2021100585A1 (ja) * 2019-11-20 2021-05-27 国立大学法人東海国立大学機構 キメラ抗原受容体遺伝子改変リンパ球の調製方法
GB201918908D0 (en) * 2019-12-19 2020-02-05 Autolus Ltd Cell
CN111264469B (zh) * 2020-02-27 2022-03-25 西安交通大学医学院第一附属医院 一种基因免疫诱导的甲状腺相关性眼病动物模型的构建方法及雷帕霉素类药物的应用
EP4127141A1 (en) * 2020-04-03 2023-02-08 Cellvie Inc. Enhancement of adoptive cell transfer
KR20230065251A (ko) 2020-08-07 2023-05-11 네오진 테라퓨틱스 비.브이. 유전적으로 조작된 t 세포를 풍부화시키기 위한 방법
JP2024503515A (ja) * 2021-01-20 2024-01-25 ネオジン セラピューティクス ビー．ブイ． 改変抗原提示細胞
EP4298120A1 (en) 2021-02-25 2024-01-03 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
WO2024058234A1 (ja) * 2022-09-13 2024-03-21 株式会社サイト－ファクト 移植用ｔ細胞およびその製造方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
AU6816194A (en) * 1993-04-20 1994-11-08 Robinson, William S. Methods and materials for treatment of individuals infected with intracellular infectious agents
EP0814838B1 (en) 1995-03-08 2003-05-14 The Scripps Research Institute Antigen presenting system and activation of t-cells
EP0969865B1 (en) 1996-05-23 2006-12-06 The Scripps Research Institute Mhc class ii antigen-presenting systems and methods for activating cd4?+ t cells
CA2280997C (en) 1997-03-11 2013-05-28 Perry B. Hackett Dna-based transposon system for the introduction of nucleic acid into dna of a cell
WO1999047687A1 (en) * 1998-03-20 1999-09-23 Genzyme Corporation Enhanced anti-tumor immunity
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US6790662B1 (en) 1999-03-12 2004-09-14 Ortho-Mcneil Pharmaceutical, Inc. Method of isolating CD8+ cells, and related hybridoma cells antibodies and polypeptides
US20040071671A1 (en) 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
US7955845B2 (en) * 2001-11-20 2011-06-07 Dana Farber Cancer Institute, Inc. Modified antigen-presenting cells
US8227432B2 (en) 2002-04-22 2012-07-24 Regents Of The University Of Minnesota Transposon system and methods of use
US7109304B2 (en) 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
US7435596B2 (en) * 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
ES2672895T3 (es) * 2005-08-05 2018-06-18 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh Generación de células T específicas de antígeno
CA2643337C (en) 2006-03-01 2016-01-12 Janssen Pharmaceutica N.V. Cancer treatment combining lymphodepleting agent with ctls and cytokines
CA2665568C (en) 2006-10-04 2018-01-09 Janssen Pharmaceutica, N.V. Preparation of inactivated artificial antigen presenting cells and their use in cell therapies
WO2009091826A2 (en) * 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
BRPI1006215A2 (pt) 2009-03-20 2019-09-24 Genentech Inc " anticorpos multiespecíficos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, método de tratamento, método de inibição de uma atividade bíologica e uso do anticorpo "
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CA2851795C (en) * 2011-10-20 2018-11-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd22 chimeric antigen receptors
AU2013204922B2 (en) * 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
US9657105B2 (en) * 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
SG11201509609SA (en) 2013-05-24 2015-12-30 Univ Texas Chimeric antigen receptor-targeting monoclonal antibodies
AU2015218239B2 (en) 2014-02-14 2019-01-31 Board Of Regents, The University Of Texas System Chimeric antigen receptors and methods of making

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3773918A4 (en) * 2019-03-05 2022-01-05 Nkarta, Inc. ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY

Also Published As

Publication number Publication date
AU2015343013B2 (en) 2020-07-16
HK1243441A1 (zh) 2018-07-13
CN107207615A (zh) 2017-09-26
KR20170075785A (ko) 2017-07-03
JP2020022504A (ja) 2020-02-13
US20170333480A1 (en) 2017-11-23
EP3536707A1 (en) 2019-09-11
AU2015343013A1 (en) 2017-05-11
WO2016073755A2 (en) 2016-05-12
WO2016073755A9 (en) 2017-07-27
WO2016073755A3 (en) 2016-06-30
AU2020250247A1 (en) 2020-11-05
US20220072041A1 (en) 2022-03-10
JP2017535284A (ja) 2017-11-30
EP3215535A2 (en) 2017-09-13

Similar Documents

Publication Publication Date Title
US20220072041A1 (en) Gene modified immune effector cells and engineered cells for expansion of immune effector cells
US20200247867A1 (en) Chimeric antigen receptors (car) to selectively target protein complexes
US20250002579A1 (en) Chimeric antigen receptors and methods of making
JP6970991B2 (ja) トランスポザーゼポリペプチド及びその使用
HK40030175A (en) Chimeric antigen receptors and methods of making
HK40105414A (zh) 突变体il-15组合物及其方法
HK40105048A (zh) 表达tlr受体的经修饰的免疫细胞
HK1243442B (en) Chimeric antigen receptors (car) to selectively target protein complexes
HK1232561B (en) Chimeric antigen receptors and methods of making
HK1232561A1 (en) Chimeric antigen receptors and methods of making

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201013

EEER Examination request

Effective date: 20201013

EEER Examination request

Effective date: 20201013

EEER Examination request

Effective date: 20201013

FZDE Discontinued

Effective date: 20240123